LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Mindful Health Solutions (MHS), one of the US’s leading providers of innovative behavioral health care, today announced that they have entered into a research collaboration agreement to inform the development of a scalable and cost-effective delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression (TRD).

伦敦，2024年5月2日（环球通讯社）--Compass Pathways plc（纳斯达克：CMPS）（“Compass”），一家致力于加速患者获得心理健康循证创新的生物技术公司，以及美国领先的创新行为医疗服务提供商之一的正念健康解决方案（MHS），今天宣布，他们已经签署了一项研究合作协议，如果批准用于治疗抵抗性抑郁症（TRD），将为COMP360 psilocybin治疗开发一种可扩展且具有成本效益的交付模式。

This is the latest of several collaborations for Compass, intended to better understand a range of potential approaches to deliver COMP360 to patients in different care settings. MHS offers comprehensive mental health care services for patients living with TRD and other mental health conditions. They focus on early adoption of advanced, interventional treatment options, as part of a long-term, holistic care model that includes medication management and psychotherapy.

这是Compass的几项合作中的最新一项，旨在更好地了解向不同护理环境中的患者提供COMP360的一系列潜在方法。MHS为患有TRD和其他心理健康状况的患者提供全面的心理保健服务。他们专注于早期采用先进的介入治疗方案，作为包括药物管理和心理治疗在内的长期整体护理模式的一部分。

MHS operates over 20 outpatient clinics located across California, Washington, Texas, and Georgia. “It is crucial that we understand how different mental health service providers are positioned to deliver COMP360 psilocybin treatment to patients, should it receive FDA approval,” said Kabir Nath, CEO of Compass Pathways.

MHS在加利福尼亚州、华盛顿州、德克萨斯州和乔治亚州设有20多家门诊诊所。Compass Pathways首席执行官卡比尔·纳特（KabirNath）表示：“如果Compass Pathways获得FDA批准，我们必须了解不同的心理健康服务提供商如何为患者提供COMP360 psilocybin治疗。”。

“By joining forces with MHS, Compass will have the opportunity to learn from a leading provider of innovative behavioral health care for people living with treatment-resistant depression and other difficult-to-treat mental health conditions.” The collaboration with MHS will include an in-depth information exchange on Compass's potential delivery model for investigational COMP360 psilocybin treatment, and how it might fit into a healthcare delivery s.

“通过与MHS的合作，Compass将有机会向患有难治性抑郁症和其他难以治疗的心理健康状况的人学习创新行为保健的领先供应商。”与MHS的合作将包括深入交流Compass用于研究性COMP360 psilocybin治疗的潜在交付模式，以及它如何适合医疗保健交付。